REcovery from DEXmedetomidine-Induced Unresponsiveness (REDEX): A Study Protocol for a Single Center, Parallel Arm, Non-Randomized, Controlled Pilot Trial in Healthy Volunteers.

PURPOSE

Dexmedetomidine (DEX) is a well-tolerated sedative drug that induces a sleep-like state. DEX sedation offers a model to study transitions between different states of consciousness (indicated by, eg, behavior, the electroencephalogram (EEG), or transcranial magnetic stimulation (TMS) evoked EEG responses). However, the effects of repeated DEX exposure on recovery are poorly understood and will be investigated in this pilot study.

PARTICIPANTS AND METHODS

We aim to enroll 12 healthy volunteers (6 females, 6 males). Although we do not expect TMS-EEG to interfere with DEX sedation, due to the paucity of evidence this study uses a parallel arm design (TMS-EEG, non-TMS-EEG). Participants will be sedated twice, one week apart, and responsiveness monitored by a click-task to auditory beeps. A 64-channel EEG and additional physiological signals will be recorded. Cognition and vigilance tests will be performed before sedation (baseline), after return of responsiveness (ROR), and before discharge. TMS-EEG will be performed at baseline, during sedation, and during recovery. Using a smartwatch and questionnaires, we will assess sleep quality, sleepiness, and experiences during sedation and TMS-EEG.

RESULTS

We will report the difference of time to ROR between the first and second study visit, and explore potential differences across sex and study arms. We will evaluate state transitions by comparing responsiveness, traditional EEG signatures, TMS-evoked EEG responses (ie, perturbational complexity index), and report on cognition and vigilance test performance.

CONCLUSION

This pilot trial will report on the effect of repeated DEX exposure on the recovery period, and the investigation of state transitions will advance our scientific understanding of altered states of consciousness. REDEX will provide valuable insights and data for designing future DEX sedation studies. Moreover, we will report on the potential of biological sex as a confounding factor and the feasibility of TMS-EEG under DEX.